Telomeres Limit Cancer Growth by Inducing Senescence: Long-Sought In Vivo Evidence Obtained  by Sedivy, John M.
Cancer Cell
PreviewsTelomeres Limit Cancer Growth  
by Inducing Senescence:  
Long-Sought In Vivo Evidence Obtained
John M. Sedivy1,2,*
1Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, 70 Ship Street, Providence, RI 02903, USA
2Center for Genomics and Proteomics, Brown University, 70 Ship Street, Providence, RI 02903, USA
*Correspondence: john_sedivy@brown.edu
DOI 10.1016/j.ccr.2007.04.014
Cellular senescence triggered by telomere dysfunction has long been hypothesized to constitute a 
tumor suppression mechanism. The evidence has come primarily from in vitro cell culture studies, 
and more indirectly from analysis of tumor specimens. Two recent studies, published in the current 
issue of Cancer Cell and online at EMBO Reports, provide direct mechanistic evidence in cleverly 
manipulated mouse cancer models. This work shows that telomere-induced senescence is as effec-
tive as apoptosis in reducing cancer incidence and is mediated by the tumor suppressor p53.Cellular senescence is an 
irreversible cell-cycle arrest 
that can occur in response 
to a variety of stresses and 
signaling imbalances. The 
first described trigger was 
simply ongoing cell divi-
sion resulting in progressive 
shortening and eventual 
malfunction of telomeres 
(Hayflick, 1965). Telomeres 
are stretches of repetitive 
DNA, which together with 
specialized proteins form 
protective structures at the 
ends of chromosomes, pre-
venting them from being 
recognized as DNA double-
strand breaks and conse-
quently degraded or fused 
by DNA repair machiner-
ies. Telomeres shorten with 
each cell division because 
DNA polymerases cannot 
fully replicate 3′ termini, a 
phenomenon referred to as 
the end-replication problem. 
Telomeres are maintained 
by a specialized RNA-tem-
plated polymerase, called 
telomerase, which is com-
posed of a catalytic protein 
subunit and a small tem-
plate RNA (Cech, 2004).
Telomerase activity is 
typically found only in 
germ cells, some stem Figure 1. Cancer Suppression Signaling Pathways Leading 
to Senescence and Apoptosis
Inappropriate signaling elicited by activation of oncogenes, usually 
an early event during tumor progression, can elicit a DNA damage 
response resulting in the activation of p53. Oncogene activation 
often also upregulates p16, either as a consequence of the DNA 
damage response or through independent mechanisms. The p16 
and p21 branches converge on pRB, whose activation strongly 
promotes senescence. Although the relative contributions of the 
p21 and p16 branches are not yet well understood, in many cases 
p16 is believed to play a crucial role. This is underscored by its 
frequent silencing during tumor progression, and evidence is ac-
cumulating that the key selective pressure is to relieve the senes-
cence checkpoint. Telomere dysfunction, expected to occur at later 
stages of tumor progression, also causes a DNA damage response 
and strongly activates p53. The manner in which activation of p53 
is channeled into either an apoptotic response or senescence is 
not well understood, but these choices appear to be strongly influ-
enced by cell type and perhaps other contexts.Cancer Cell 11, Maycells, and transiently in 
some proliferative cells of 
renewable tissues. In the 
absence of telomerase, 
telomeres shorten by 50–
200 base pairs with each 
round of replication. When 
telomeres become criti-
cally short and incapable 
of end protection, most 
cells undergo senescence 
(Shay and Wright, 2005). 
Telomere-induced senes-
cence has been shown 
to share many compo-
nents of the DNA dam-
age response triggered by 
DNA double-strand breaks 
(von Zglinicki et al., 2005). 
Soon after the discovery 
of telomerase, its upregu-
lation was documented 
in the majority of cancer 
cells, presumably to confer 
the capability for exten-
sive proliferation. The role 
of telomere shortening in 
senescence was formally 
demonstrated by the ability 
of experimental telomerase 
expression to immortalize 
normal somatic cells (Bod-
nar et al., 1998).
In the last decade it 
became apparent that, in 
addition to telomere short-
ening, many stresses and/ 2007 ©2007 Elsevier Inc. 389
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activation of some oncogenes, can 
trigger cellular senescence in nor-
mal cells (Ben-Porath and Weinberg, 
2004; Collado and Serrano, 2006). In 
spite of the plethora of stimuli, in the 
great majority of cases senescence 
proceeds through one (or both) of 
two central signaling pathways, lead-
ing to the activation of the p53 and 
retinoblastoma (pRB) tumor sup-
pressor proteins (Figure 1). The two 
key effectors that distinguish these 
pathways are the cyclin-dependent 
kinase inhibitors p21 (CDKN1A) and 
p16 (CDKN2A) (Campisi, 2005; Her-
big and Sedivy, 2006). p21 is tran-
scriptionally activated by p53, and 
this pathway is the primary mediator 
of telomere- and genotoxic stress-
induced senescence (d’Adda di 
Fagagna et al., 2004). The p16-pRB 
pathway mediates many forms of 
nongenotoxic stress-induced senes-
cence. Oncogene-induced senes-
cence can activate both the p16-pRB 
and p21-p53 pathways.
The cardinal features of cellular 
senescence are irreversibility of the 
arrest, profound changes in gene 
expression patterns, and the ability 
of senescent cells to persist for long 
periods of time. Although both senes-
cence and apoptosis are regulated by 
the p53 pathway, they are considered 
to be physiologically distinct phenom-
ena; in fact, many senescent cells 
display a distinct resistance to apop-
totic cell death. It is important to note, 
however, that the great majority of 
information on senescence has come 
from cell culture models, and that until 
very recently, even the existence of 
this process in vivo at any appreciable 
level was on tenuous footing. Solid 
evidence has now come from mouse 
models in which expression of acti-
vated oncogenes (or loss of a tumor 
suppressor) resulted in the develop-
ment of benign lesions comprised of 
demonstrably senescent cells (Col-
lado and Serrano, 2006). Furthermore, 
the malignant tumors that grew out 
of these lesions had inactivated and 
bypassed the senescence response. 
Similarly, benign melanocytic nevi in 
human skin contain cells that express 
oncogenic BRAF and are senescent.390 Cancer Cell 11, May 2007 ©2007 ElsThese findings indicate that onco-
gene-induced senescence occurs 
in vivo and suggest that the role of 
the senescence response is to pre-
vent oncogene-expressing cells from 
progressing to malignancy. Simi-
larly compelling evidence for the in 
vivo existence of telomere-induced 
senescence has been lacking. This is 
mainly because the laboratory mouse 
is a less than ideal model system: this 
species has very long telomeres, and 
many tissues express significant lev-
els of telomerase. A mouse that com-
pletely lacks telomerase activity, due 
to a germline knockout of the RNA 
template component, is apparently 
normal and healthy. After successive 
generations, allowing for sufficient 
telomere shortening, the mice dis-
play premature aging phenotypes, 
although their tumor susceptibility is 
not significantly altered. The latter is 
due to surveillance performed by the 
p53 pathway, which was shown to 
induce apoptosis of cells that have 
suffered telomere dysfunction.
On the basis of these studies it 
was widely believed that telomere-
induced senescence simply did not 
exist in the mouse. Carol Greider 
(Feldser and Greider, 2007) and 
Sandy Chang (Cosme-Blanco et 
al., 2007) recently undertook some 
clever mouse genetics to reinves-
tigate this issue more closely and 
investigated consequences of an 
oncogenic challenge in the pres-
ence of shortened telomeres when 
apoptotic mechanisms were geneti-
cally blunted. Both groups used a 
knockout of the telomerase RNA to 
generate animals with short telo-
meres. The Greider group first com-
bined the telomerase knockout with 
a transgene that drives Myc onco-
gene expression in B cells. As pre-
viously observed, short telomeres 
strongly inhibited tumorigenesis by 
inducing apoptosis. To suppress 
apoptosis, Bcl2 overexpression 
was engineered in bone marrow 
cells using in vitro retrovirus vector 
infection, and the cells were sub-
sequently transplanted into lethally 
irradiated syngeneic recipient ani-
mals. As expected, transplanted 
bone marrow cells with normal telo-evier Inc.meres invariably gave rise to highly 
aggressive tumors. Surprisingly, 
when telomeres were shortened by 
removing telomerase activity, palpa-
ble tumors did not develop for over 
100 days. The answer was found 
by histological examination, which 
revealed small encapsulated tumor 
masses in lymph nodes that dis-
played clear signs of senescence, 
such as senescence-associated β-
galactosidase activity and expres-
sion of the tumor suppressor p16.
The Chang group used a knockin 
of a specific allele of p53, Arg172Pro, 
that abrogates induction of apop-
totic responses but maintains com-
petence for cell-cycle arrest, and 
investigated the occurrence of spon-
taneous tumors in older mice with 
normal or short telomeres. In this 
experimental setting, strong tumor 
suppression was also observed, with 
clear evidence of senescence activa-
tion in diverse cellular compartments. 
Interestingly, although the mice dis-
played profound spontaneous cancer 
resistance, their life spans were not 
prolonged. This may be due to the 
activation of senescence in numer-
ous proliferative compartments, 
which would be expected to nega-
tively affect survival; indeed, the mice 
showed some phenotypes of prema-
ture aging. Senescence did not, how-
ever, effectively suppress chemical 
carcinogen-induced skin cancer, a 
situation where both apoptosis and 
senescence may be needed.
Both groups concluded that in 
most (although perhaps not all) cases 
senescence was as effective as apop-
tosis in reducing cancer incidence, 
and that in all cases examined the 
senescence response was mediated 
by the p53 pathway. The main point of 
these studies is that telomere-depen-
dent senescence does in fact occur 
and can effectively suppress cancer 
in the mouse. The existence of this 
mechanism has been a key assump-
tion of the senescence tumor suppres-
sion hypothesis, so it is very reassur-
ing to have it confirmed in vivo. More 
importantly, it strongly reinforces the 
notion that cellular senescence, either 
oncogene- or telomere-induced, is 
of equal importance to apoptosis in 
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been well documented that genotoxic 
stress, including telomere dysfunc-
tion, triggers apoptosis in some cell 
types, whereas in others senescence 
is the primary response. While such 
choices are not well understood, it is 
comforting that, in B cells, which pre-
fer apoptosis, senescence can act as 
a robust backup system. Finally, the 
possibility that oncogene- and telo-
mere-induced senescence may act 
as reinforcing, two-tiered defense 
systems, especially in human can-
cers, needs to be considered.The small intestine’s epithelial lining 
is characterized by invagination of the 
so-called crypts into surrounding tis-
sue and by the presence of finger-like 
protrusions (i.e., villi) extending into 
the lumen (Figure 1A). In the lower 
region of each crypt, there may be 
four to six stem cells (Marshman et 
al., 2002). Following their prolifera-
tive expansion in the crypt, progeni-
tors differentiate into enterocytes, 
goblet cells, and enteroendocrine 
cells as they migrate upward along 
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villus surface, or into Paneth cells as 
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crypt. Enterocytes undergo apopto-
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surface only days after their birth.
The β-catenin protein has previ-
ously been established to have a 
central role in regulating proliferation, 
differentiation, and migration in intes-
tinal epithelium (Batlle et al., 2002; 
Ireland et al., 2004; van de Wetering 
et al., 2002). Most of the cell’s pool of 
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β-catenin is tethered to E-cadherin as 
an adherens junction component to 
mediate intercellular adhesion. A less 
abundant “free” pool of β-catenin can 
serve as a transcriptional coactivator 
upon its translocation to the nucleus 
and binding to DNA-binding proteins 
of the T cell factor (TCF) family (Fig-
ures 1B and 1C). In most cells, the 
free pool of β-catenin is tightly regu-
lated by a destruction complex com-
posed of the adenomatous polyposis 
coli (APC) and Axin tumor suppres-
d  
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